enGene Therapeutics ENGN
NASDAQ ENGN
$1.98 -0.02 (-1.00%)
At close: Oct 1, 2026 · 4:00 PM EDT

enGene Therapeutics (ENGN) Long-Term Debt Issuances (2023 - 2026)

Updated

enGene Therapeutics (ENGN) reported Long-Term Debt Issuances of $25 million for fiscal Q1 2026 (quarter ended Jan 31, 2026).

Analysis

enGene Therapeutics (ENGN) Long-Term Debt Issuances (2023 - 2026) Analysis & Trends

For FY2024 (ended Oct 31, 2024), enGene Therapeutics posted Long-Term Debt Issuances of $22.5 million, down 40.8% from FY2023.

  • By fiscal year, Long-Term Debt Issuances came in at $38 million in FY2023 (+106.5%) and $18.4 million in FY2022.
  • The fiscal Q1 2026 figure ranks as the highest quarterly Long-Term Debt Issuances since fiscal Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Issuance (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 1.98 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 enGene Therapeutics 134.03 Mn 134.03 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jan 31, 2026 25.00 Mn
Jan 31, 2024 22.50 Mn
Jul 31, 2023 30.00 Mn
API Access

enGene Therapeutics Long-Term Debt Issuances API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-issuances&ticker=ENGN&period=max&api_key=YOUR_API_KEY